Horn, L., Brahmer, J., Reck, M., Borghaei, H., Spigel, D. R., Steins, M., … Paz-Ares, L. (2015). 3010 Phase, randomized trial (CheckMate 057) of nivolumab (NIVO) vs docetaxel (DOC) in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): Subgroup analyses and patient reported outcomes (PROs). In European Journal of Cancer (Vol. 51, pp. S599–S599). Elsevier BV. https://doi.org/10.1016/s0959-8049(16)31655-0

Horn, L., J. Brahmer, M. Reck, H. Borghaei, D. R. Spigel, M. Steins, N. E. Ready, et al. “3010 Phase, randomized trial (CheckMate 057) of nivolumab (NIVO) vs docetaxel (DOC) in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): Subgroup analyses and patient reported outcomes (PROs).” In European Journal of Cancer, 51:S599–S599. Elsevier BV, 2015. https://doi.org/10.1016/s0959-8049(16)31655-0.

Horn L, Brahmer J, Reck M, Borghaei H, Spigel DR, Steins M, et al. 3010 Phase, randomized trial (CheckMate 057) of nivolumab (NIVO) vs docetaxel (DOC) in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): Subgroup analyses and patient reported outcomes (PROs). In: European Journal of Cancer. Elsevier BV; 2015. p. S599–S599.

Horn, L., et al. “3010 Phase, randomized trial (CheckMate 057) of nivolumab (NIVO) vs docetaxel (DOC) in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): Subgroup analyses and patient reported outcomes (PROs).” European Journal of Cancer, vol. 51, Elsevier BV, 2015, pp. S599–S599. Crossref, doi:10.1016/s0959-8049(16)31655-0.

Horn L, Brahmer J, Reck M, Borghaei H, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhäufl MJ, Burgio MA, Fayette J, Gettinger SN, Harbison CT, Li A, Finckenstein FG, Paz-Ares L. 3010 Phase, randomized trial (CheckMate 057) of nivolumab (NIVO) vs docetaxel (DOC) in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): Subgroup analyses and patient reported outcomes (PROs). European Journal of Cancer. Elsevier BV; 2015. p. S599–S599.